Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Development and Validation of an Individualized Immune Prognostic Signature in Early-Stage Nonsquamous Non-Small Cell Lung Cancer.

JAMA oncology - 1 Nov 2017

Li Bailiang, Cui Yi, Diehn Maximilian, Li Ruijiang

Abstract excerpt

IMPORTANCE: The prevalence of early-stage non-small cell lung cancer (NSCLC) is expected to increase with recent implementation of annual screening programs. Reliable prognostic biomarkers are needed to identify patients at a high risk for recurrence to guide adjuvant therapy. OBJECTIVE: To develop a robust, individualized immune signature that can estimate prognosis in patients with early-stage nonsquamous...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adenocarcinoma
Share to Adenocarcinoma of Lung
Share to Databases, Genetic

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Neoplasm Staging

Share to Pneumonectomy

Share to Predictive Value of Tests

Share to Proportional Hazards Models

Share to Tumor Microenvironment

Source

Open in PubMed Open full text

Identifiers

PMID: 28687838
DOI: 10.1001/jamaoncol.2017.1609
PMCID: PMC5710196

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Development and Validation of an Individualized Immune Prognostic Signature in Early-Stage Nonsquamous Non-Small Cell Lung Cancer.PMID 28687838Read ↗

A new immune signature for survival prediction and immune checkpoint molecules in lung adenocarcinoma.Semantic proximity Read ↗

Systematic construction and validation of an immune prognostic model for lung adenocarcinomaSemantic proximity Read ↗

Identification of an immune signature predicting prognosis risk of patients in lung adenocarcinomaSemantic proximity Read ↗

Construction of a Prognostic Immune Signature for Squamous-Cell Lung Cancer to Predict Survival.Semantic proximity Read ↗

Immune landscape and a novel immunotherapy-related gene signature associated with clinical outcome in early-stage lung adenocarcinoma.Semantic proximity Read ↗

Integrating Tumor and Stromal Gene Expression Signatures With Clinical Indices for Survival Stratification of Early-Stage Non–Small Cell Lung CancerSemantic proximity Read ↗

Characterizing heterogeneity of non-small cell lung tumour microenvironment to identify signature prognostic genes.Semantic proximity Read ↗

Analysis of expression differences of immune genes in non-small cell lung cancer based on TCGA and ImmPort data sets and the application of a prognostic modelSemantic proximity Read ↗

Validation of an Immune-related Gene Pair Index as a Prognostic Marker of Early-Stage Lung Squamous Cell CarcinomaSemantic proximity Read ↗

Construction of a Prognostic Model of Non-small Cell Lung Cancer Based on TCGA and ImmPort Databases and Analysis of Its Correlation With Tumor MicroenvironmentSemantic proximity Read ↗

Individualized Prognostic Score for Lung Adenocarcinoma Based on Immune StatusSemantic proximity Read ↗

Identification and validation of an inflammatory response-related signature for predicting prognosis and immunotherapeutic response in non-small cell lung cancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.